MCID: VRL010
MIFTS: 59

Viral Hepatitis

Categories: Infectious diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases, Liver diseases, Immune diseases

Aliases & Classifications for Viral Hepatitis

MalaCards integrated aliases for Viral Hepatitis:

Name: Viral Hepatitis 12 55 3 15 73
Hepatitis, Viral, Animal 44 73
Viral Hepatitis with Hepatic Coma 12
Animal Viral Hepatitis 12
Human Viral Hepatitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1884
MeSH 44 D006524

Summaries for Viral Hepatitis

Disease Ontology : 12 A hepatitis that involves viral infection causing inflammation of the liver.

MalaCards based summary : Viral Hepatitis, also known as hepatitis, viral, animal, is related to non-a-e hepatitis and hepatitis e. An important gene associated with Viral Hepatitis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and PI3K-Akt signaling pathway. The drugs Peginterferon alfa-2a and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

CDC : 3 Know More Hepatitis

Wikipedia : 76 Viral hepatitis is liver inflammation due to a viral infection. It may present in acute (recent... more...

Related Diseases for Viral Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Viral Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
# Related Disease Score Top Affiliating Genes
1 non-a-e hepatitis 33.5 ALB F2
2 hepatitis e 31.6 ALB CD40LG F2 GPT TNF
3 hepatic coma 31.3 ALB F2 GPT
4 hepatitis c 31.3 GGT1 GPT HFE IFNA1 IFNA2 KRT18
5 hepatitis d 31.2 CD40LG F2 GPT IFNA2
6 hepatitis a 31.2 AFP ALB CD40LG F2 GPT IFNA2
7 acute liver failure 30.8 ALB F2 GPT SLC17A5
8 typhoid fever 30.8 ALB F2 TNF
9 protein-energy malnutrition 30.5 ALB GPT TNF
10 peritonitis 30.3 ALB F2 TNF
11 alcohol abuse 30.2 ABCB7 GGT1 GPT SLC17A5
12 portal hypertension 30.1 ALB F2 GPT TNF
13 alpha-1-antitrypsin deficiency 30.1 ALB HFE SERPINA1
14 alcoholic liver cirrhosis 30.0 AFP ALB F2 SLC17A5
15 aplastic anemia 29.8 FAS FASLG HFE TNF
16 purpura 29.8 CD40LG F2 TNF
17 hepatic encephalopathy 29.8 ALB F2 GPT SLC17A5 TNF
18 arteries, anomalies of 29.8 ALB F2 TLR9 TNF
19 schistosomiasis 29.6 ALB CD40LG F2 TNF
20 cholecystitis 29.6 ALB F2 GPT KRT18
21 scrub typhus 29.5 CD40LG GPT SLC17A5 TNF
22 hepatitis 29.4 AFP F2 FASLG GGT1 GPT IFNA1
23 hepatitis b 29.3 AFP ALB F2 FGL2 GGT1 GPT
24 fatty liver disease 29.3 GGT1 GPT HFE KRT18 SLC17A5 TNF
25 lichen planus 29.3 MX1 TLR9 TNF
26 alcoholic hepatitis 28.9 ALB F2 GPT KRT18 SLC17A5 TNF
27 nonalcoholic steatohepatitis 28.7 F2 GPT HFE KRT18 SLC17A5 TNF
28 autoimmune hepatitis 28.6 CD40LG F2 FAS GGT1 GPT SEPSECS
29 liver cirrhosis 28.5 AFP ALB F2 GGT1 GPT HFE
30 primary biliary cirrhosis 28.4 ALB CD40LG F2 GGT1 SEPSECS
31 liver disease 25.4 ABCB7 AFP ALB F2 FAS GGT1
32 fulminant viral hepatitis 12.2
33 porphyria cutanea tarda 11.2
34 paraquat poisoning 11.0 GPT SLC17A5
35 lymphomatoid granulomatosis 11.0 IFNA1 IFNA2
36 antipyrine metabolism 11.0 ALB F2
37 hepatoportal sclerosis 11.0 F2 GPT
38 pyridoxine deficiency 11.0 GPT SLC17A5
39 squamous papillomatosis 10.9 IFNA1 IFNA2
40 mucinous cystadenofibroma 10.9 AFP SERPINA1
41 epstein-barr virus hepatitis 10.8
42 polyembryoma 10.8 AFP SERPINA1
43 marburg hemorrhagic fever 10.8 F2 TNF
44 fascioliasis 10.8 ALB GPT SLC17A5
45 severe hemophilia a 10.8 F2 IFNA1 TNF
46 kashin-beck disease 10.7 FAS TNF
47 gastroenteritis 10.7 ALB IFNA1 TNF
48 esophageal varix 10.7 AFP ALB F2
49 hepatic vascular disease 10.7 AFP ALB F2
50 vein disease 10.7 AFP ALB F2

Graphical network of the top 20 diseases related to Viral Hepatitis:



Diseases related to Viral Hepatitis

Symptoms & Phenotypes for Viral Hepatitis

GenomeRNAi Phenotypes related to Viral Hepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 AFP ALB FAS FASLG FGL2 GGT1

MGI Mouse Phenotypes related to Viral Hepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 CD40LG TNF F2 FAS FASLG FGL2
2 digestive/alimentary MP:0005381 9.8 TNF F2 FAS FASLG HFE TLR9
3 liver/biliary system MP:0005370 9.56 TNF FAS FASLG HFE ABCB7 KRT18
4 mortality/aging MP:0010768 9.47 TNF CD40LG F2 FAS FASLG FGL2

Drugs & Therapeutics for Viral Hepatitis

Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 266)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
2
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
3
Ribavirin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 36791-04-5 37542
4
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
5
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
6
Sofosbuvir Approved Phase 4,Phase 2,Phase 3 1190307-88-0 45375808
7
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 154598-52-4 64139
8
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
9
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 134678-17-4 60825
10
Pravastatin Approved Phase 4 81093-37-0 54687
11
Simeprevir Approved Phase 4 923604-59-5 66576988
12
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2 376348-65-1 3002977
13
Iron Approved Phase 4 7439-89-6 23925
14
Simvastatin Approved Phase 4 79902-63-9 54454
15
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
16
Emtricitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 143491-57-0 60877
17
Ethambutol Approved Phase 4,Phase 2,Phase 3 74-55-5 3279 14052
18
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2 54-85-3 3767
19
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
20
Rifampicin Approved Phase 4,Phase 2,Phase 3 13292-46-1 5458213 5381226
21
Zidovudine Approved Phase 4,Phase 3,Phase 2 30516-87-1 35370
22
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
23
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
24
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
27
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
28
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
29
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
30
Adefovir Investigational Phase 4 106941-25-7
31 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Obesity Agents Phase 4
37 Hepatitis C Antibodies Phase 4,Phase 2,Not Applicable
38 insulin Phase 4,Phase 3
39 Insulin, Globin Zinc Phase 4,Phase 3
40 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Anticholesteremic Agents Phase 4
42 Atorvastatin Calcium Phase 4 134523-03-8
43 Calcium, Dietary Phase 4
44 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
45 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
46 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
47 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 368)
# Name Status NCT ID Phase Drugs
1 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
2 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
3 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
4 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
5 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
6 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
7 Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B Completed NCT01639092 Phase 4 Tenofovir;Tenofovir;Entecavir
8 Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B Completed NCT01639066 Phase 4 Tenofovir;Entecavir;Tenofovir
9 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
10 Interferon α 2b Pharmacovigilance Study Completed NCT01841775 Phase 4 interferon α 2b + ribavirin
11 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
12 Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126) Completed NCT00117494 Phase 4 Pravastatin;Rosuvastatin
13 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
14 Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Completed NCT01195181 Phase 4 peginterferon plus ribavirin
15 Efficacy of Silymarin for Acute Hepatitis Completed NCT00412763 Phase 4 Silymarin (Silybum marianum)
16 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Completed NCT01327547 Phase 4 Maraviroc;Placebo
17 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
18 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
19 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
20 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
21 Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh. Recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
22 Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Recruiting NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
23 Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission Recruiting NCT02937779 Phase 4 Tenofovir disoproxil fumarate
24 Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 Active, not recruiting NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
25 Strategic Timing of Antiretroviral Treatment Active, not recruiting NCT00867048 Phase 4 All licensed antiretroviral medications
26 DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) Not yet recruiting NCT03537196 Phase 4 Sofosbuvir 400 mg and Daclatasvir 60 mg;Sofosbuvir 400 mg and Daclatasvir 90 mg;Sofosbuvir 400 mg and Daclatasvir 60 mg and Ribavirin;Sofosbuvir 400 mg and Daclatasvir 60 mg for 24 weeks
27 Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients Terminated NCT00122668 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitor
28 Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Terminated NCT00122655 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitors
29 Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C Terminated NCT02120274 Phase 4 Vitamin D;Vitamin B 12
30 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT01766115 Phase 4 Telaprevir
31 A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 Unknown status NCT02371408 Phase 2, Phase 3 ravidasvir hydrochloride;sofosbuvir;ribavirin
32 Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
33 A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B Unknown status NCT01172392 Phase 3 Pegylated interferon-alpha-2a;Nucleotidic or Nucleosidic Treatment
34 BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection Unknown status NCT01641016 Phase 2, Phase 3 efavirenz
35 Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C Completed NCT00265642 Phase 3 Irbesartan;placebo
36 Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Completed NCT01595685 Phase 3 Telbivudine;Entecavir
37 Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed NCT00116454 Phase 3 131 I-lipiodol
38 Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients Completed NCT00946595 Phase 2, Phase 3 efavirenz/emtricitabin/tenofovir;lopinavir/ritonavir
39 Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices Completed NCT00657397 Phase 3 Methadone
40 Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding Completed NCT00640263 Phase 3 lopinavir/ritonavir (LPV/r);Lamivudine (3TC)
41 Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) Completed NCT00573001 Phase 3 Tenofovir/Emtricitabine (Truvada) and Nevirapine;Tenofovir/Emtricitabine/Efavirenz (Atripla);Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia);Tenofovir/Emtricitabine (Truvada) and Zidovudine
42 Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) Completed NCT00495651 Phase 3 Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis;Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis
43 Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) Completed NCT00495326 Phase 2, Phase 3 Nevirapine based therapy;Efavirenz based therapy;Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
44 Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load Completed NCT00454337 Phase 3 FTC/TDF + EFV or LPV/R +T20;FTC/TDF + EFV or LPV/R
45 Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136 Completed NCT00421551 Phase 3 Darunavir;ritonavir
46 Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients Completed NCT00391638 Phase 2, Phase 3 TRUVADA (EMTRICITABINE + TENOFOVIR DF)
47 Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE Completed NCT00383734 Phase 3
48 Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130) Completed NCT00302822 Phase 3 enfuvirtide;emtricitabine/tenofovir;lopinavir or efavirenz
49 Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL) Completed NCT00301561 Phase 3
50 Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA) Completed NCT00226434 Phase 3

Search NIH Clinical Center for Viral Hepatitis

Cochrane evidence based reviews: hepatitis, viral, animal

Genetic Tests for Viral Hepatitis

Anatomical Context for Viral Hepatitis

MalaCards organs/tissues related to Viral Hepatitis:

41
Liver, Testes, Kidney, T Cells, Bone, Brain, Thyroid

Publications for Viral Hepatitis

Articles related to Viral Hepatitis:

(show top 50) (show all 1125)
# Title Authors Year
1
Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. ( 29354656 )
2018
2
Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. ( 29751763 )
2018
3
Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-I+ inhibitors in clinical practice. ( 29391775 )
2018
4
A Cross-Sectional Study of Viral Hepatitis Perception among Residents from Southeast and North Regions of Brazil. ( 29364166 )
2018
5
An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. ( 29757684 )
2018
6
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). ( 29977962 )
2018
7
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis. ( 29947010 )
2018
8
Psychological Disorders and Quality of Life Among Patients With Chronic Viral Hepatitis: A Single-Center Cross-Sectional Study With Pair-Matched Healthy Controls. ( 29847395 )
2018
9
Opisthorchiasis and viral hepatitis b: clinical cases. ( 29602941 )
2018
10
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study. ( 29844854 )
2018
11
Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. ( 29427537 )
2018
12
Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. ( 29963464 )
2018
13
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? ( 29443655 )
2018
14
Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis. ( 29309052 )
2018
15
Viral hepatitis: Biomarker for HBV therapy discontinuation. ( 29362470 )
2018
16
Lumbar synovial cyst with chronic viral hepatitis: A case series and literature review. ( 29724648 )
2018
17
Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. ( 29874147 )
2018
18
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )
2018
19
Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. ( 29847179 )
2018
20
Safety of biologic agents for psoriasis in patients with viral hepatitis. ( 29345515 )
2018
21
Anti-infective potential of catechins and their derivatives against viral hepatitis. ( 29399578 )
2018
22
High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. ( 29399285 )
2018
23
Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: real-world data from a nationwide cohort study in Taiwan. ( 29753054 )
2018
24
Association of viral hepatitis and bipolar disorder: a nationwide population-based study. ( 29929549 )
2018
25
Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. ( 29432255 )
2018
26
Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. ( 29708985 )
2018
27
Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review. ( 29786879 )
2018
28
CROI 2018: Highlights of Viral Hepatitis. ( 29727295 )
2018
29
Management of chronic viral hepatitis in the hematological patient. ( 29415584 )
2018
30
IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis. ( 29400707 )
2018
31
Acute Viral Hepatitis: Beyond A, B, and C. ( 29751873 )
2018
32
Viral Hepatitis Recommendations for Solid-Organ Transplant Recipients and Donors. ( 29381580 )
2018
33
Comparison of Dynamic Changes Among Various Prognostic Scores in Viral Hepatitis-Related Acute Liver Failure. ( 29735790 )
2018
34
Report from the International Conference on Viral Hepatitis - 2017. ( 29369303 )
2018
35
Changes in acute viral hepatitis epidemiology in the Turkish adult population: A multicenter study. ( 29749324 )
2018
36
Acute Exacerbation to Autoimmune Hepatitis Mimicking Acute Viral Hepatitis-A Case Series and Review of Literature. ( 29743801 )
2018
37
Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. ( 29367206 )
2018
38
The evolution of the burden of viral hepatitis from 1990 to 2013: still an open challenge to global public health policy. ( 28848754 )
2017
39
[Serological markers of viral hepatitis B and C in children with sickle cell disease monitored in the Pediatrics Department at the University Hospital of Bobo-Dioulasso (Burkina Faso)]. ( 28417347 )
2017
40
Viral hepatitis and liver cancer. ( 28893941 )
2017
41
Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. ( 28860489 )
2017
42
Type I interferon receptor signaling delays Kupffer cell replenishment during acute fulminant viral hepatitis. ( 29274730 )
2017
43
A Diagnostic Laboratory-Based Study on Frequency and Distribution of Viral Hepatitis B and C Among Sudanese. ( 29399232 )
2017
44
Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. ( 28887164 )
2017
45
Current status and strategies for viral hepatitis control in Korea. ( 28942620 )
2017
46
Current status and strategies for the control of viral hepatitis A in Korea. ( 28942621 )
2017
47
Age-standardized mortality rates related to viral hepatitis in Brazil. ( 28760138 )
2017
48
Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. ( 29404481 )
2017
49
Maximizing Donors with Viral hepatitis in the Current Era. ( 28846183 )
2017
50
Viral hepatitis C in Poland in the Silesian Province between 2005-2014. ( 29936822 )
2017

Variations for Viral Hepatitis

Expression for Viral Hepatitis

Search GEO for disease gene expression data for Viral Hepatitis.

Pathways for Viral Hepatitis

Pathways related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 FAS FASLG IFNA1 IFNA2 TLR9 TNF
2
Show member pathways
12.85 FAS FASLG IFNA1 IFNA2 MX1 TNF
3
Show member pathways
12.69 CD40LG FAS FASLG IFNA1 IFNA2 TNF
4
Show member pathways
12.37 CD40LG FASLG TLR9 TNF
5
Show member pathways
12.32 FAS FASLG IFNA1 IFNA2 TNF
6
Show member pathways
12.22 ALB F2 GGT1 TNF
7
Show member pathways
12.2 FAS FASLG IFNA1 IFNA2 TNF
8
Show member pathways
12.19 FAS FASLG IFNA1 IFNA2 MX1 TLR9
9 12.15 CD40LG FAS FASLG IFNA1 TLR9 TNF
10 12.14 CD40LG FAS FASLG TNF
11 12.11 IFNA1 IFNA2 TLR9 TNF
12
Show member pathways
12.03 FAS FASLG TLR9 TNF
13
Show member pathways
11.93 FAS FASLG KRT18 TNF
14
Show member pathways
11.89 FAS FASLG IFNA1 IFNA2 TNF
15
Show member pathways
11.66 CD40LG FASLG TNF
16 11.64 IFNA2 TLR9 TNF
17 11.41 FAS FASLG TNF
18 11.36 CD40LG TLR9 TNF
19 11.28 AFP ALB F2
20 11.25 FAS FASLG TNF
21 10.47 FAS FASLG TLR9 TNF

GO Terms for Viral Hepatitis

Cellular components related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 AFP ALB CD40LG F2 FAS FASLG
2 external side of plasma membrane GO:0009897 9.55 CD40LG F2 FASLG HFE TNF
3 extracellular space GO:0005615 9.44 AFP ALB CD40LG F2 FASLG GGT1

Biological processes related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 CD40LG FAS IFNA2 TLR9 TNF
2 cellular protein metabolic process GO:0044267 9.83 AFP ALB F2 SERPINA1
3 blood coagulation GO:0007596 9.8 F2 IFNA1 IFNA2 SERPINA1
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.73 FAS FASLG TNF
5 regulation of signaling receptor activity GO:0010469 9.73 CD40LG F2 FASLG IFNA1 IFNA2 TNF
6 apoptotic signaling pathway GO:0097190 9.72 FAS FASLG TNF
7 B cell differentiation GO:0030183 9.71 CD40LG IFNA1 IFNA2
8 defense response GO:0006952 9.71 IFNA1 IFNA2 MX1 TNF
9 type I interferon signaling pathway GO:0060337 9.69 IFNA1 IFNA2 MX1
10 humoral immune response GO:0006959 9.65 IFNA1 IFNA2 TNF
11 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.57 FAS FASLG
12 tumor necrosis factor-mediated signaling pathway GO:0033209 9.55 CD40LG FAS FASLG KRT18 TNF
13 acute-phase response GO:0006953 9.54 F2 HFE SERPINA1
14 B cell proliferation GO:0042100 9.5 CD40LG IFNA1 IFNA2
15 regulation of immunoglobulin secretion GO:0051023 9.43 CD40LG TNF
16 extrinsic apoptotic signaling pathway GO:0097191 9.26 FAS FASLG KRT18 TNF
17 necroptotic signaling pathway GO:0097527 8.8 FAS FASLG TNF

Molecular functions related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.13 CD40LG FASLG TNF
2 cytokine activity GO:0005125 9.02 CD40LG FASLG IFNA1 IFNA2 TNF

Sources for Viral Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....